Table II.
Clinicopathological and experimental characteristics of GBMs with or without TERT promoter mutation.
| TERT promoter mutation, n (%) | |||
|---|---|---|---|
| Variable | + | − | P-value |
| Age, years | 56.5±8.3 | 47.2±14.6 | 0.050 |
| Sex | <0.001 | ||
| Male | 12 (100) | 0 (0) | |
| Female | 4 (30.8) | 9 (69.2) | |
| Tumor size, cm | 4.70±1.63 | 4.79±0.75 | 0.943 |
| ATRX mutation | 1.00 | ||
| + | 7 (87.5) | 1 (12.5) | |
| − | 6 (75.0) | 2 (25.0) | |
| ATRX amplification | 0.391 | ||
| + | 0 (0) | 1 (100) | |
| − | 14 (63.6) | 8 (36.4) | |
| EGFR mutation | 0.117 | ||
| + | 11 (91.7) | 1 (8.3) | |
| − | 4 (57.1) | 3 (42.9) | |
| EGFR amplification | 0.102 | ||
| + | 10 (76.9) | 3 (23.1) | |
| − | 4 (40.0) | 6 (60.0) | |
| CDKN2A deletion | 0.116 | ||
| + | 12 (70.6) | 5 (29.4) | |
| − | 1 (20.0) | 4 (80.0) | |
| PTEN mutation | 1.00 | ||
| + | 3 (75.0) | 1 (25.0) | |
| − | 10 (83.3) | 2 (16.7) | |
| PTEN deletion | 0.102 | ||
| + | 10 (76.9) | 3 (23.1) | |
| − | 4 (40.0) | 6 (60.0) | |
| Subtype | 0.176 | ||
| Classical | 6 (100) | 0 (0) | |
| Mesenchymal | 2 (40.0) | 3 (60.0) | |
| Proneural | 3 (60.0) | 2 (40.0) | |
| Not determined | 5 (55.6) | 4 (44.4) | |
| In vivo tumor formation | 0.004 | ||
| + | 12 (80.0) | 3 (20.0) | |
| − | 0 (0) | 5 (100) | |
Data are presented as the mean ± standard deviation. TERT, telomerase reverse transcriptase gene; GBM, glioblastoma multiforme; ATRX, α-thalassemia/mental retardation syndrome X-linked; EGFR, epidermal growth factor receptor; PTEN, phosphatase and tensin homolog; CDKN2A, cyclin dependent kinase inhibitor 2A.